Do analysts prefer ISPC or VIVS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iSpecimen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, ISPC or VIVS?

iSpecimen has higher revenue and earnings than VivoSim Labs. VivoSim Labs is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iSpecimen $1.93M 1.76 -$10.49M -$72.26 N/A VivoSim Labs $130K 9.78 -$13.84M -$5.36 N/A

Is ISPC or VIVS more profitable?

iSpecimen has a net margin of -1,080.16% compared to VivoSim Labs' net margin of -10,567.17%. VivoSim Labs' return on equity of -277.62% beat iSpecimen's return on equity. Company Net Margins Return on Equity Return on Assets iSpecimen -1,080.16% -584.65% -142.48% VivoSim Labs -10,567.17% -277.62% -153.77%

Does the media favor ISPC or VIVS?

In the previous week, iSpecimen had 2 more articles in the media than VivoSim Labs. MarketBeat recorded 4 mentions for iSpecimen and 2 mentions for VivoSim Labs. iSpecimen's average media sentiment score of 0.57 beat VivoSim Labs' score of 0.28 indicating that iSpecimen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iSpecimen 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive VivoSim Labs 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend TBIO or VIVS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telesis Bio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TBIO or VIVS more profitable?

Telesis Bio has a net margin of -336.59% compared to VivoSim Labs' net margin of -10,567.17%. Telesis Bio's return on equity of 0.00% beat VivoSim Labs' return on equity. Company Net Margins Return on Equity Return on Assets Telesis Bio -336.59% N/A -61.89% VivoSim Labs -10,567.17% -277.62% -153.77%

Do analysts prefer VIVS or BFRGW?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bullfrog AI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, VIVS or BFRGW?

Bullfrog AI has lower revenue, but higher earnings than VivoSim Labs. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio VivoSim Labs $130K 9.78 -$13.84M -$5.36 N/A Bullfrog AI $116.67K N/A N/A N/A N/A

Is VIVS or BFRGW more profitable?

Bullfrog AI has a net margin of 0.00% compared to VivoSim Labs' net margin of -10,567.17%. Bullfrog AI's return on equity of 0.00% beat VivoSim Labs' return on equity. Company Net Margins Return on Equity Return on Assets VivoSim Labs -10,567.17% -277.62% -153.77% Bullfrog AI N/A N/A N/A

Do analysts prefer VIVS or OABIW?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 OmniAb 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, VIVS or OABIW?

OmniAb has higher revenue and earnings than VivoSim Labs. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio VivoSim Labs $130K 9.78 -$13.84M -$5.36 N/A OmniAb $38.46M N/A N/A N/A N/A

Is VIVS or OABIW more profitable?

OmniAb has a net margin of 0.00% compared to VivoSim Labs' net margin of -10,567.17%. OmniAb's return on equity of 0.00% beat VivoSim Labs' return on equity. Company Net Margins Return on Equity Return on Assets VivoSim Labs -10,567.17% -277.62% -153.77% OmniAb N/A N/A N/A

Does the media favor TMO or VIVS?

In the previous week, Thermo Fisher Scientific had 37 more articles in the media than VivoSim Labs. MarketBeat recorded 39 mentions for Thermo Fisher Scientific and 2 mentions for VivoSim Labs. Thermo Fisher Scientific's average media sentiment score of 1.26 beat VivoSim Labs' score of 0.28 indicating that Thermo Fisher Scientific is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Thermo Fisher Scientific 30 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive VivoSim Labs 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

VivoSim Labs (VIVS) Competitors

$0.36 -0.10 (-22.16%)

As of 04:00 PM Eastern

Compare

VIVS vs. ISPC, TBIO, BFRGW, OABIW, and TMO

Should you buy VivoSim Labs stock or one of its competitors? VivoSim Labs's main competitors and comparable companies include iSpecimen (ISPC), Telesis Bio (TBIO), Bullfrog AI (BFRGW), OmniAb (OABIW), and Thermo Fisher Scientific (TMO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does VivoSim Labs compare to iSpecimen?

iSpecimen (NASDAQ:ISPC) and VivoSim Labs (NASDAQ:VIVS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

iSpecimen has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market. Comparatively, VivoSim Labs has a beta of 1.47, indicating that its stock price is 47% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iSpecimen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

iSpecimen has higher revenue and earnings than VivoSim Labs. VivoSim Labs is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iSpecimen	$1.93M	1.76	-$10.49M	-$72.26	N/A
VivoSim Labs	$130K	9.78	-$13.84M	-$5.36	N/A

In the previous week, iSpecimen had 2 more articles in the media than VivoSim Labs. MarketBeat recorded 4 mentions for iSpecimen and 2 mentions for VivoSim Labs. iSpecimen's average media sentiment score of 0.57 beat VivoSim Labs' score of 0.28 indicating that iSpecimen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iSpecimen	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
VivoSim Labs	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

iSpecimen has a net margin of -1,080.16% compared to VivoSim Labs' net margin of -10,567.17%. VivoSim Labs' return on equity of -277.62% beat iSpecimen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iSpecimen	-1,080.16%	-584.65%	-142.48%
VivoSim Labs	-10,567.17%	-277.62%	-153.77%

13.6% of iSpecimen shares are owned by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are owned by institutional investors. 12.2% of iSpecimen shares are owned by company insiders. Comparatively, 2.5% of VivoSim Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

iSpecimen beats VivoSim Labs on 9 of the 12 factors compared between the two stocks.

How does VivoSim Labs compare to Telesis Bio?

Telesis Bio (NASDAQ:TBIO) and VivoSim Labs (NASDAQ:VIVS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

Telesis Bio has a net margin of -336.59% compared to VivoSim Labs' net margin of -10,567.17%. Telesis Bio's return on equity of 0.00% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telesis Bio	-336.59%	N/A	-61.89%
VivoSim Labs	-10,567.17%	-277.62%	-153.77%

37.6% of Telesis Bio shares are owned by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are owned by institutional investors. 24.5% of Telesis Bio shares are owned by company insiders. Comparatively, 2.5% of VivoSim Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telesis Bio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, VivoSim Labs had 2 more articles in the media than Telesis Bio. MarketBeat recorded 2 mentions for VivoSim Labs and 0 mentions for Telesis Bio. VivoSim Labs' average media sentiment score of 0.28 beat Telesis Bio's score of 0.00 indicating that VivoSim Labs is being referred to more favorably in the news media.

Company	Overall Sentiment
Telesis Bio	Neutral
VivoSim Labs	Neutral

VivoSim Labs has lower revenue, but higher earnings than Telesis Bio. VivoSim Labs is trading at a lower price-to-earnings ratio than Telesis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telesis Bio	$225.09M	0.00	-$47.72M	-$20.52	N/A
VivoSim Labs	$130K	9.78	-$13.84M	-$5.36	N/A

Telesis Bio has a beta of 2.43, indicating that its stock price is 143% more volatile than the broader market. Comparatively, VivoSim Labs has a beta of 1.47, indicating that its stock price is 47% more volatile than the broader market.

Summary

Telesis Bio beats VivoSim Labs on 7 of the 13 factors compared between the two stocks.

How does VivoSim Labs compare to Bullfrog AI?

VivoSim Labs (NASDAQ:VIVS) and Bullfrog AI (NASDAQ:BFRGW) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, VivoSim Labs had 2 more articles in the media than Bullfrog AI. MarketBeat recorded 2 mentions for VivoSim Labs and 0 mentions for Bullfrog AI. VivoSim Labs' average media sentiment score of 0.28 beat Bullfrog AI's score of 0.00 indicating that VivoSim Labs is being referred to more favorably in the media.

Company	Overall Sentiment
VivoSim Labs	Neutral
Bullfrog AI	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bullfrog AI	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Bullfrog AI has a net margin of 0.00% compared to VivoSim Labs' net margin of -10,567.17%. Bullfrog AI's return on equity of 0.00% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VivoSim Labs	-10,567.17%	-277.62%	-153.77%
Bullfrog AI	N/A	N/A	N/A

Bullfrog AI has lower revenue, but higher earnings than VivoSim Labs.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VivoSim Labs	$130K	9.78	-$13.84M	-$5.36	N/A
Bullfrog AI	$116.67K	N/A	N/A	N/A	N/A

8.2% of VivoSim Labs shares are held by institutional investors. 2.5% of VivoSim Labs shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

VivoSim Labs beats Bullfrog AI on 6 of the 9 factors compared between the two stocks.

How does VivoSim Labs compare to OmniAb?

VivoSim Labs (NASDAQ:VIVS) and OmniAb (NASDAQ:OABIW) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

OmniAb has a net margin of 0.00% compared to VivoSim Labs' net margin of -10,567.17%. OmniAb's return on equity of 0.00% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VivoSim Labs	-10,567.17%	-277.62%	-153.77%
OmniAb	N/A	N/A	N/A

8.2% of VivoSim Labs shares are held by institutional investors. 2.5% of VivoSim Labs shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, VivoSim Labs had 2 more articles in the media than OmniAb. MarketBeat recorded 2 mentions for VivoSim Labs and 0 mentions for OmniAb. VivoSim Labs' average media sentiment score of 0.28 beat OmniAb's score of 0.00 indicating that VivoSim Labs is being referred to more favorably in the media.

Company	Overall Sentiment
VivoSim Labs	Neutral
OmniAb	Neutral

OmniAb has higher revenue and earnings than VivoSim Labs.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VivoSim Labs	$130K	9.78	-$13.84M	-$5.36	N/A
OmniAb	$38.46M	N/A	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
OmniAb	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

VivoSim Labs beats OmniAb on 5 of the 9 factors compared between the two stocks.

How does VivoSim Labs compare to Thermo Fisher Scientific?

Thermo Fisher Scientific (NYSE:TMO) and VivoSim Labs (NASDAQ:VIVS) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

Thermo Fisher Scientific has a net margin of 15.04% compared to VivoSim Labs' net margin of -10,567.17%. Thermo Fisher Scientific's return on equity of 17.09% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Thermo Fisher Scientific	15.04%	17.09%	8.12%
VivoSim Labs	-10,567.17%	-277.62%	-153.77%

89.2% of Thermo Fisher Scientific shares are owned by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are owned by institutional investors. 0.3% of Thermo Fisher Scientific shares are owned by insiders. Comparatively, 2.5% of VivoSim Labs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Thermo Fisher Scientific presently has a consensus target price of $619.41, indicating a potential upside of 3.46%. Given Thermo Fisher Scientific's stronger consensus rating and higher probable upside, research analysts plainly believe Thermo Fisher Scientific is more favorable than VivoSim Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Thermo Fisher Scientific	0 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.79
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Thermo Fisher Scientific had 37 more articles in the media than VivoSim Labs. MarketBeat recorded 39 mentions for Thermo Fisher Scientific and 2 mentions for VivoSim Labs. Thermo Fisher Scientific's average media sentiment score of 1.26 beat VivoSim Labs' score of 0.28 indicating that Thermo Fisher Scientific is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Thermo Fisher Scientific	30 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
VivoSim Labs	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Thermo Fisher Scientific has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, VivoSim Labs has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market.

Thermo Fisher Scientific has higher revenue and earnings than VivoSim Labs. VivoSim Labs is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Thermo Fisher Scientific	$44.56B	4.97	$6.70B	$18.59	32.20
VivoSim Labs	$130K	9.78	-$13.84M	-$5.36	N/A

Summary

Thermo Fisher Scientific beats VivoSim Labs on 13 of the 16 factors compared between the two stocks.

Get VivoSim Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VIVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VIVS vs. The Competition

Export

Metric	VivoSim Labs	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.64M	$9.58B	$7.06B	$12.95B
Dividend Yield	N/A	1.47%	2.58%	10.20%
P/E Ratio	N/A	62.58	269.75	24.74
Price / Sales	9.78	104.71	652.34	108.60
Price / Cash	N/A	26.16	28.89	37.44
Price / Book	-0.87	5.15	11.27	6.42
Net Income	-$13.84M	$56.66B	$3.45B	$347.12M
7 Day Performance	8.88%	3.54%	3.56%	2.48%
1 Month Performance	-58.56%	0.51%	-0.58%	-1.04%
1 Year Performance	-79.12%	23.97%	77.52%	23.22%

VivoSim Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VIVS VivoSim Labs	0.9483 of 5 stars	$0.36 -22.2%	N/A	-73.2%	$1.64M	$130K	N/A	20	Gap Down
ISPC iSpecimen	0.52 of 5 stars	$2.20 +14.6%	N/A	-95.7%	$2.92M	$1.93M	N/A	60	Gap Up High Trading Volume
TBIO Telesis Bio	N/A	$0.00 flat	N/A	-95.0%	$2K	$225.09M	N/A	200
BFRGW Bullfrog AI	N/A	$0.12 +2.2%	N/A	-74.3%	$0.00	$116.67K	N/A	2	Gap Down
OABIW OmniAb	N/A	$0.05 -35.4%	N/A	-71.4%	$0.00	$28.94M	N/A	106	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VIVS) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

VivoSim Labs (VIVS) Competitors

VIVS vs. ISPC, TBIO, BFRGW, OABIW, and TMO

How does VivoSim Labs compare to iSpecimen?

Summary

How does VivoSim Labs compare to Telesis Bio?

Summary

How does VivoSim Labs compare to Bullfrog AI?

Summary

How does VivoSim Labs compare to OmniAb?

Summary

How does VivoSim Labs compare to Thermo Fisher Scientific?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIVS vs. The Competition

VivoSim Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

VivoSim Labs (VIVS) Competitors

VIVS vs. ISPC, TBIO, BFRGW, OABIW, and TMO

How does VivoSim Labs compare to iSpecimen?

Which has more volatility & risk, ISPC or VIVS?

Do analysts prefer ISPC or VIVS?

Which has better earnings and valuation, ISPC or VIVS?

Does the media favor ISPC or VIVS?

Is ISPC or VIVS more profitable?

Do institutionals & insiders believe in ISPC or VIVS?

Summary

How does VivoSim Labs compare to Telesis Bio?

Is TBIO or VIVS more profitable?

Do institutionals and insiders have more ownership in TBIO or VIVS?

Do analysts recommend TBIO or VIVS?

Does the media refer more to TBIO or VIVS?

Which has better valuation & earnings, TBIO or VIVS?

Which has more volatility & risk, TBIO or VIVS?

Summary

How does VivoSim Labs compare to Bullfrog AI?

Does the media favor VIVS or BFRGW?

Do analysts prefer VIVS or BFRGW?

Is VIVS or BFRGW more profitable?

Which has stronger earnings and valuation, VIVS or BFRGW?

Do insiders & institutionals have more ownership in VIVS or BFRGW?

Summary

How does VivoSim Labs compare to OmniAb?

Is VIVS or OABIW more profitable?

Do institutionals and insiders hold more shares of VIVS or OABIW?

Does the media refer more to VIVS or OABIW?

Which has stronger valuation and earnings, VIVS or OABIW?

Do analysts prefer VIVS or OABIW?

Summary

How does VivoSim Labs compare to Thermo Fisher Scientific?

Is TMO or VIVS more profitable?

Do institutionals and insiders believe in TMO or VIVS?

Do analysts prefer TMO or VIVS?

Does the media favor TMO or VIVS?

Which has more volatility and risk, TMO or VIVS?

Which has better valuation and earnings, TMO or VIVS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIVS vs. The Competition

VivoSim Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools